Alnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 30, 2018--
Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics
company, announced today that it will report financial results for the
third quarter ending September 30, 2018 on Wednesday, November 7, 2018,
before the U.S. financial markets open.
Management will provide an update on the Company and discuss third
quarter 2018 results as well as expectations for the future via
conference call on Wednesday, November 7, 2018 at 8:30 am ET. To access
the call, please dial 800-667-5617 (domestic) or 334-323-0509
(international) five minutes prior to the start time and refer to
conference ID 7650424. A replay of the call will be available beginning
at 11:30 am ET on the day of the call. To access the replay, please dial
888-203-1112 (domestic) or 719-457-0820 (international) and refer to
conference ID 7650424.
A live audio webcast of the call will be available on the Investors
section of the Company’s website, www.alnylam.com.
An archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a new class of
innovative medicines with the potential to improve the lives of people
afflicted with rare genetic, cardio-metabolic, hepatic infectious, and
central nervous system (CNS) diseases. Based on Nobel Prize-winning
science, RNAi therapeutics represent a powerful, clinically validated
approach for the treatment of a wide range of severe and debilitating
diseases. Founded in 2002, Alnylam is delivering on a bold vision to
turn scientific possibility into reality, with a robust discovery
platform. ONPATTRO™ (patisiran) lipid complex injection,
available in the U.S. for the treatment of the polyneuropathy of
hereditary transthyretin-mediated (hATTR) amyloidosis in adults, is
Alnylam’s first U.S. FDA-approved RNAi therapeutic. In the EU, ONPATTRO
is approved for the treatment of hATTR amyloidosis in adults with stage
1 or stage 2 polyneuropathy. Alnylam has a deep pipeline of
investigational medicines, including three product candidates that are
in late-stage development. Looking forward, Alnylam will continue to
execute on its "Alnylam 2020" strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable pipeline
of RNAi-based medicines to address the needs of patients who have
limited or inadequate treatment options. Alnylam employs over 800 people
worldwide and is headquartered in Cambridge, MA. For more information
about our people, science and pipeline, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam
or on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181030006043/en/
Source: Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom,
(Investors and Media)